Seelos Therapeutics logo

Seelos Therapeutics(OTC) SEEL

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-100%
5 YearN/A
1 Year+9,900%
1 Month+0%
N/A
Seelos Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-14
Seelos Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-19
1 month+0%USD 0.002026-08-14
3 month+0%USD 0.002026-06-11
Year to date+9,900%USD 0.002025-12-31
1 year+9,900%USD 0.002025-09-12
Since inception-100%USD 14,784.022019-01-24

Seelos Therapeutics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.01M

Net Income (TTM)

$4.09M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 20, 2024

SEEL News

ETF made of $100 dollar bills

Why Seelos Therapeutics Stock Is Jumping Today

Keith SpeightsJun 1, 2021
A medical professional using a microscope

Why Seelos Therapeutics Dived by 24% Today

Eric VolkmanMay 17, 2021
Thumbs up from businessman

Why Seelos Therapeutics Stock Is Skyrocketing Today

Keith SpeightsMar 12, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) and respiratory conditions. The company is advancing several key clinical candidates, including SLS-002 for major depressive disorder and SLS-005 for amyotrophic lateral sclerosis.

Products and Services
  • SLS-002: Intranasal racemic ketamine for acute suicidal ideation
  • SLS-005: Protein stabilizer targeting amyotrophic lateral sclerosis
  • SLS-006: Partial dopamine agonist for Parkinson's disease treatment
Growth Outlook
  • Strong pipeline with multiple clinical-stage candidates in development
  • Focus on CNS disorders, a growing market with significant unmet needs
  • Potential for partnerships to enhance research and development capabilities
Financial Highlights
  • Q2 2024 revenue of $376,000, showing growth from previous quarters
  • Net income of $1.71 million in Q2 2024, a significant improvement
  • Cash and cash equivalents of $294,000 as of June 30, 2024
Seelos Therapeutics, Inc. operates in the biotechnology sector, emphasizing the discovery and development of therapies for serious medical conditions. The company’s innovative approach targets critical areas within CNS and respiratory health, which are increasingly recognized for their potential market growth. The clinical pipeline includes promising candidates that address urgent health challenges, particularly in mental health and neurodegenerative diseases. Recent financial performance indicates a positive trajectory, with a notable increase in revenue and net income in the latest quarter. This improvement reflects the company's ongoing commitment to advancing its clinical programs and enhancing shareholder value. The financial position, while still developing, shows potential for future growth, especially with strategic partnerships and collaborations that may arise as the company progresses. Overall, Seelos Therapeutics, Inc. presents an intriguing opportunity for investors interested in the biotechnology sector, particularly those focused on innovative solutions for complex health issues.
AI Generated • Oct 3, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

16

CEO

Raj Mehra, PhD, MBA

Website

www.seelostherapeutics.com

Headquarters

New York City, NY 10022, US

SEEL Financials

Key Financial Metrics (TTM)

Gross Margin

-1267.09%

Operating Margin

-1838.36%

Net Income Margin

-1719.56%

Return on Equity

171.72%

Return on Capital

N/A

Return on Assets

-699.19%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$1.22M

Operating Income

-$29.81M

EBITDA

$4.26M

Operating Cash Flow

-$13.27M

Capital Expenditure

$0.00

Free Cash Flow

-$13.27M

Cash & ST Invst.

$294.00K

Total Debt

$10.16M

Seelos Therapeutics Performance Analysis

Seelos Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20232023-12-31USD 2,203,000N/A
Seelos Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-3020.8%
Q42023-12-3160.8%
Q12024-03-31-11.3%
Q22024-06-30-35.1%
Seelos Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -2,790.45N/A
20222022-12-31USD -2,655.28-4.8%
20232023-12-31USD -989.53-62.7%
Seelos Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-30131.7%
Q42023-12-31-169.0%
Q12024-03-3151.0%
Q22024-06-30116.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

$376.00K

+11.9%

Gross Profit

-$379.00K

-217.7%

Gross Margin

-1.01%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

8

N/A

Net Income

$1.71M

+105.8%

EBITDA

$1.75M

+105.9%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Total Cash

$294.00K

-95.0%

Total Debt

$10.16M

-33.8%

Accounts Receivable

$188.00K

-56.4%

Inventory

$0.00

-100.0%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$10.20M

-17.9%

Return on Assets

-6.99%

N/A

Return on Invested Capital

1.21%

N/A

Free Cash Flow

-$972.00K

+83.5%

Operating Cash Flow

-$972.00K

+83.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VIRIVirios Therapeutics, Inc.
$0.16+12.40%
BLPHBellerophon Therapeutics, Inc.
$0.01-36.84%
TFFPTFF Pharmaceuticals, Inc.
$0.07-60.05%
KERNAkerna Corp.
$0.31+36.94%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$221.30-3.16%
BACBank of America
$51.39-4.76%
CRWVCoreWeave
$65.78-15.46%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$110.54-13.35%

Questions About SEEL

What is the current price of Seelos Therapeutics?

Seelos Therapeutics is trading at N/A per share.

What is the 52-week range for Seelos Therapeutics?

Over the past 52 weeks, Seelos Therapeutics has traded between N/A and N/A.

How much debt does Seelos Therapeutics have?

As of the most recent reporting period, Seelos Therapeutics reported total debt of $14.23M.

How much cash does Seelos Therapeutics have on hand?

Seelos Therapeutics reported $3.00M in cash and cash equivalents in its most recent financial results.

What is Seelos Therapeutics’s dividend yield?

Seelos Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services